Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
FDA approval · 2022-12-07FDA Approved: VIVIMUSTA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved VIVIMUSTA (bendamustine hydrochloride) from Azurity Pharmaceuticals under Original Application NDA212209.
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.
-
FDA approval · 2022-10-11FDA Approved: BORTEZOMIB — Original Application (Somerset Therapeutics LLC)
FDA approved a generic version of Bortezomib under an Original Application (ANDA 211898) for Somerset Therapeutics LLC. The product is used …
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Original Application (Pharmacyclics LLC)
The FDA approved the original application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC, establishing its initial approval for mantle cel…
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
FDA approval · 2022-08-03FDA Approved: CALQUENCE — Original Application (AstraZeneca Pharmaceuticals LP)
FDA approves CALQUENCE (acalabrutinib) from AstraZeneca in an original application for mantle cell lymphoma.
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (Hospira, Inc.)
FDA approved Hospira's generic version of bortezomib for injection under ANDA208460, enabling a generic option for the same indications as t…
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (Dr.Reddy's Laboratories, Inc.)
FDA approval of Dr. Reddy's Laboratories' original ANDA for Bortezomib, enabling a generic version of the proteasome inhibitor.
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original generic application for bortezomib, a proteasome inhibitor used to treat multiple myeloma and …
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approves a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC. The document indicates FDA approval of the…
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Apotex Corp)
FDA approves Apotex Corp's original application for a generic Bortezomib product under ANDA205533.